Ivermectin as a Novel Therapy in COVID-19 Treatment

Tanta University

Status and phase: Completed; Phase 3; Phase 2

Conditions: COVID

Treatments: Drug: Ivermectin

Study type: Interventional

Funder types: Other

Identifiers

NCT04403555

tanta covid treatment

Details and patient eligibility

About

Efficacy of Ivermectin in COVID-19 treatment

Full description

Clinical Study Evaluating the Efficacy of Ivermectin in COVID-19 treatment

Enrollment: 164 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• All Adult Patients aging from 20 to 65 years-old with COVID-19 confirmed by pharyngeal swab PCR.

Exclusion criteria

• Allergy or contraindication to the drugs used in the study.
• Pregnant and lactating mothers.
• Patients with cardiac problems.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

164 participants in 2 patient groups

Ivermectin

Experimental group

Description:

Ivermectin plus standard of care treatment Dose 2 tablets 12mg per day for 3 days

Treatment:

Drug: Ivermectin

Standard of care

No Intervention group

Description:

Standard of care treatment